ROBERT SHIH: Open Payments
NPI 1760589147 · HAVERHILL, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,353 in 210 payments from 33 companies in 2025. Trend: 2023 $4,475 · 2024 $4,798 · 2025 $4,353
Food & beverage: $4,334Education: $19
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $545 |
| AstraZeneca Pharmaceuticals LP | 19 | $498 |
| PFIZER INC. | 19 | $358 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $257 |
| Lilly USA, LLC | 11 | $248 |
| Teva Pharmaceuticals USA, Inc. | 15 | $243 |
| Otsuka America Pharmaceutical, Inc. | 11 | $216 |
| Amgen Inc. | 5 | $200 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 10 | $199 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $197 |
Products named: REXULTI, JARDIANCE, UBRELVY, VRAYLAR, XIFAXAN, CAPLYTA, AIRSUPRA, FARXIGA.
Industry payments across MA — which companies pay providers there.
